DOCS Stock Recent News

Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.

Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2024 after market close on February 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ b.

Upgraded Doximity to a buy rating due to recent share price pullback, stronger engagement metrics, and deeper client relationships, creating a compelling entry point. DOCS reported 20% y/y revenue growth in 2Q25, surpassing management's guidance, with increased user adoption and higher revenue per user driving performance. The adoption of AI-driven tools and expanded Client Portal access are enhancing the Company's value proposition, leading to higher engagement and better-targeted advertising for pharma clients.

In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne Medical, X-Fab Silicon Foundries, and ArcerlorMittal. Analysts' recommendations range from Strong Buy to Strong Sell, covering diverse sectors such as healthcare, technology, energy, and consumer goods.

Five stocks have strong momentum for January. These are: DOCS, LUV, ALK, DBX, PARRA.

The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/.

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.

As of Sept. 24, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.